Aprea Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.6M
- Price
- $0.605
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.80%
- Volume
- 249.9K
About
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding12.6M
Computed float9.0M
Float / shares71.1%
Cash runway (months)38
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001781983
Websitehttps://www.aprea.com
AI Summary
AI-generated1/15
minorneutralother
Aprea Therapeutics to Present at October Conferences
Aprea Therapeutics announced that President and CEO Oren Gilad will present at the 2026 Maxim Growth Summit on October 14 in New York City and at the Regional Biotechnology Conference on October 15 in Doylestown, PA.
The Maxim appearance is a 9am ET fireside chat with an on-demand webcast for registered attendees; the regional conference features panel discussions.
No new clinical or financial data accompanies the announcement; the release reiterates the company's lead programs APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor), both in clinical development for solid tumors.